30 results
DEFM14A
AMTI
Applied Molecular Transport Inc.
21 Nov 23
Proxy related to merger
9:16am
for the treatment of ulcerative colitis (“UC”), chronic pouchitis and rheumatoid arthritis (“RA”). AMTI conducted a broad Phase 2 clinical program for AMT-101 … therapy in biologic naïve patients with moderately to severely active UC, and the FILLMORE trial as a monotherapy in patients with chronic antibiotic
8-K
EX-99.1
AMTI
Applied Molecular Transport Inc.
22 Dec 22
Other Events
5:20pm
partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis
- Strong cash position of $76M reported in Q3 2022
SOUTH SAN … by the positive data generated with AMT-101 in chronic pouchitis, which has been granted Orphan Drug Designation in this indication. We will be seeking a partner
8-K
EX-99.1
AMTI
Applied Molecular Transport Inc.
7 Nov 22
Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
meeting with FDA to discuss advancing oral AMT-101 monotherapy to Phase 3 in chronic pouchitis, an orphan indication with no FDA-approved products … on the positive top-line data from our FILLMORE monotherapy trial in patients with chronic pouchitis, was an important milestone for the company” said Tahir
8-K
EX-99.1
noo4hr0ngue
4 Aug 22
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
j79i94 pl
6 Jul 22
Other Events
8:01am
8-K
EX-99.1
sv24hm7fx266nw08hx
18 May 22
Applied Molecular Transport Provides Strategy Update
8:18am
8-K
EX-99.1
y9biqwls54pzaqun
9 May 22
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
8-K
f7c2w onyqv
25 Apr 22
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE
8:01am
8-K
EX-99.1
uwx7s17k7oendw p5yng
25 Apr 22
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE
8:01am
424B5
n9fr4p6l as44z77cd5
28 Mar 22
Prospectus supplement for primary offering
9:27pm
S-3
cznvm7cksjigzfmn4qwg
11 Mar 22
Shelf registration
5:03pm
8-K
EX-99.1
2kpqj wbx6
24 Feb 22
Applied Molecular Transport Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
kl4j26y07esl75
10 Nov 21
Applied Molecular Transport Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
v3vcjsb63jue p8njuh
10 Aug 21
Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:05pm